assesses the leukemic clone, and the analytical error is the only source of variability. For this reason, we retain that the genomic approach should not be classified with the quantification of the chimeric transcript as a surrogate of disease response.
In recent years, important technical progress has influenced laboratory procedures used to monitor CML patients. Concerning RNA analysis, the main improvements have aimed at reducing the impact of in vitro RNA instability, as well as such critical pre-analytical steps as RNA extraction and retro-transcription. Instead, the applicability of the genomic approach is still greatly hampered by the need to retrieve the breakpoint sequence of each patient. This limitation could be overcome by next-generation sequencing [5] , but the technology required is far from being broadly accessible for routine applications, and the genomic approach is limited to pilot studies. As pointed out [1] , another technical opportunity for the analysis of both DNA and RNA, is the use of digital PCR. Crampe and Langabeer also dealt with parameters such as LOD, LOQ and UOM, which are crucial for the correct characterization of analytical methods as demanded by the continuous evolution of the laboratory equipments. In our previous letter [2] we reported the example of a clinical study [6] in which the authors drafted a method based on the amplification of genomic DNA by nested PCR, increasing the number of replicates in the hope of enhancing the sensitivity. The authors gave several clinical readings of their ''deep scanning'' results [6, 7] , since the potential for drug discontinuation makes these subjects a pressing issue. However, the significance of these data is open to discussion, since increasing the replicates only ameliorates the statistics and thus the accuracy, but it has no effect on the sensitivity. It is important to note that this observation doesn't contrast with the principle of digital PCR. Digital PCR is based on the partition of the sample into discrete sub-units, each behaving as an individual PCR reaction. The elevated number of partitions (in the order of tens of thousands) greatly improves the statistics and the accuracy of the method; the meaning of sample partition is fairly similar to the increase in the number of replicates, but with greater effect. However, the main advantage of digital PCR is that each partition contains either zero or one (or, at most, a few) template molecules, minimizing the effects of competition between target sequences. End-point PCR amplification of each partition returns a positive/negative pattern that is used to absolutely quantify the target sequence by Poisson statistics (i.e. digital PCR doesn't rely on the number of amplification cycles). This is the reason behind the higher sensitivity of digital PCR resulting in a real reduction in the LOD/LOQ.
In conclusion, molecular monitoring by conventional RNA reverse transcription and quantitative PCR is still the recommended method with broadly available consensus guidelines. Nevertheless, operators should be aware of the limitations of this procedure and be conscious of the opportunities offered by the new technologies. Furthermore, we strengthen our considerations on the need to fully understand and characterize analytical methods prior to any clinical application.
